scholarly journals Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development

Author(s):  
Anna Arnal-Estapé ◽  
Giorgia Foggetti ◽  
Jacqueline H. Starrett ◽  
Don X. Nguyen ◽  
Katerina Politi
2014 ◽  
Author(s):  
Steven M. Dubinett ◽  
Pierre Massion ◽  
Ignacio Wistuba ◽  
Avrum Spira

Author(s):  
Yue Zhao ◽  
Yuxia Liu ◽  
Shuang Li ◽  
Zhaoyun Peng ◽  
Xiantao Liu ◽  
...  

Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide (Ferlay et al., Int J Cancer 136:E359–386, 2015). In addition, lung cancer is associated with the highest mortality among all cancer types (Wu et al., Exp Ther Med 16:3004–3010, 2018). Previous studies report that microbiota play an important role in lung cancer. Notably, changes in lung and gut microbiota, are associated with progression of lung cancer. Several studies report that lung and gut microbiome promote lung cancer initiation and development by modulating metabolic pathways, inhibiting the function of immune cells, and producing pro-inflammatory factors. In addition, some factors such as microbiota dysbiosis, affect production of bacteriotoxins, genotoxicity and virulence effect, therefore, they play a key role in cancer progression. These findings imply that lung and gut microbiome are potential markers and targets for lung cancer. However, the role of microbiota in development and progression of lung cancer has not been fully explored. Purpose The aim of this study was to systemically review recent research findings on relationship of lung and gut microbiota with lung cancer. In addition, we explored gut–lung axis and potential mechanisms of lung and gut microbiota in modulating lung cancer progression. Conclusion Pulmonary and intestinal flora influence the occurrence, development, treatment and prognosis of lung cancer, and will provide novel strategies for prevention, diagnosis, and treatment of lung cancer.


Oncotarget ◽  
2015 ◽  
Vol 6 (26) ◽  
pp. 21802-21815 ◽  
Author(s):  
Ri Cui ◽  
Taewan Kim ◽  
Matteo Fassan ◽  
Wei Meng ◽  
Hui-Lung Sun ◽  
...  

2021 ◽  
Vol 22 (15) ◽  
pp. 8332
Author(s):  
Marek Fol ◽  
Piotr Koziński ◽  
Jakub Kulesza ◽  
Piotr Białecki ◽  
Magdalena Druszczyńska

Although the therapeutic effect of mycobacteria as antitumor agents has been known for decades, recent epidemiological and experimental studies have revealed that mycobacterium-related chronic inflammation may be a possible mechanism of cancer pathogenesis. Mycobacterium tuberculosis and non-tuberculous Mycobacterium avium complex infections have been implicated as potentially contributing to the etiology of lung cancer, whereas Mycobacterium ulcerans has been correlated with skin carcinogenesis. The risk of tumor development with chronic mycobacterial infections is thought to be a result of many host effector mechanisms acting at different stages of oncogenesis. In this paper, we focus on the nature of the relationship between mycobacteria and cancer, describing the clinical significance of mycobacteria-based cancer therapy as well as epidemiological evidence on the contribution of chronic mycobacterial infections to the increased lung cancer risk.


2017 ◽  
Vol 12 (8) ◽  
pp. S1544 ◽  
Author(s):  
B. Gao ◽  
M. Peyton ◽  
C. Huang ◽  
H. Park ◽  
L. Girard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document